AUA 2025: Long-Term Outcomes of Treatment of Recurrent or New-Onset Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel
AUA 2025 phase 3 OLYMPUS trial, UGN-101, low-grade upper tract urothelial carcinoma, upper tract urothelial carcinoma tumor recurrence, uTRACT registry (NCT05874921).